ArticleScientific reports2025
Retrospective analysis of 274 cases suspected vaginal intraepithelial neoplasia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Vaginal intraepithelial neoplasia (VaIN) is a precancerous lesion for invasive vaginal cancer, which is highly malignant and difficult to treat. This study aimed to identify the risk factors for VaIN and emphasize the importance of screening and monitoring patients with a history of cervical intraepithelial neoplasia and ongoing human papillomavirus (HPV) infection. Patients suspected of having VaIN were admitted to the Department of Gynecology and Obstetrics at the Affiliated Suzhou Hospital of Nanjing Medical University between February 2014 and August 2022. Medical records of these patients were retrospectively reviewed. A total of 274 patients underwent colposcopy due to suspected VaIN, and the diagnosis was confirmed in 167 patients based on biopsy pathology reports. Multivariate analysis in which odds ratios (ORs) with a 95% confidence interval (95% CI) were calculated revealed that vaccine-related HPV-infected patients (OR = 4.30, 95% CI: 1.75-10.58), and postmenopausal patients (OR = 5.94, 95% CI: 1.95-18.09), had a significantly increased risk of developing high-grade VaIN. However, patients with prior surgical treatment had a reduced risk (OR = 0.58, 95% CI: 0.34-0.99), which may be attributed to regular monitoring. HPV16, 58, 52, and 33 were among the most prevalent HPV types, with HPV16 positivity associated with higher-grade VaIN. Patients with concurrent cervical high-grade squamous epithelial lesions also exhibited high-grade VaIN, indicating a potential link between cervical and vaginal intraepithelial lesions. Our study highlights the complex interplay between risk factors such as prior surgical treatment, human papillomavirus infection, and menstrual status in the progression of VaIN. This underscores the importance of comprehensive evaluation and management strategies for VaIN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.